Investor Presentation First Nine Months of 2022
62
Investor presentation First nine months of 2022
Novo NordiskⓇ
Patient access to AOM is improving with around 80% commercial
formulary access in the US and 16 countries in IO
WegovyⓇ Patient Access Pathway in NAO
People with obesity¹
Restricted reimbursement for SaxendaⓇ is progressing
EXAMPLES
Obesity prevalence
in adults
~100 M
Commercially covered
~60 M
WegovyⓇ
formulary access
~50 M
Estimated WegovyⓇ
opt-ins
Note: Obesity is defined as BMI > 30.
-30 M²
~125k
people on WegovyⓇ today
1 Prevalence: Adult obesity facts. Centers for Disease Control and Prevention. Accessed Mar 2021
2 Includes commercial and non-commercial (Fx. US Department of Defense and Medicaid) channels
米
(+)
BMI > 30
with one co-morbidity
BMI > 35
With pre-diabetes and risk of CV
~60% coverage by private insurance, 20% of
which includes restricted/unrestricted coverage
SaxendaⓇ reimbursed in April 2020 in selected
patient groups
SaxendaⓇ now launched in 71 countries with 16 countries
offering restricted reimbursement; 9 have come in the
last 2 yearsView entire presentation